APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Carcinoma

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neuroendocrine Carcinoma Market Analysis and Forecast 2026-2032

22 December 2025196 pages

Choose your research edition.

Industry ResearchNeuroendocrine Carcinoma Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Carcinoma Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Carcinoma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Carcinoma Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Carcinoma Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neuroendocrine Carcinoma market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neuroendocrine Carcinoma is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Neuroendocrine Carcinoma include Teva, Novartis, Pfizer, Abbvie, Valeant, Mateon, Lexicon, Jubilant and Ipsen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Neuroendocrine Carcinoma, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neuroendocrine Carcinoma, also provides the revenue of main regions and countries. Of the upcoming market potential for Neuroendocrine Carcinoma, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuroendocrine Carcinoma revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neuroendocrine Carcinoma market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neuroendocrine Carcinoma revenue, projected growth trends, production technology, application and end-user industry.

Neuroendocrine Carcinoma Segment by Company

Teva

Novartis

Pfizer

Abbvie

Valeant

Mateon

Lexicon

Jubilant

Ipsen

F.Hoffmann-La Roche

Chiasma

Advanced Accelerator

Neuroendocrine Carcinoma Segment by Type

Somatostatin Analogs

Chemotherapy

Targeted Therapy

Neuroendocrine Carcinoma Segment by Application

Oncology Centres

Clinics

Hospital

Ambulatory Surgery Centres

Neuroendocrine Carcinoma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Carcinoma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Carcinoma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Carcinoma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neuroendocrine Carcinoma in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neuroendocrine Carcinoma company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroendocrine Carcinoma revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuroendocrine Carcinoma Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Somatostatin Analogs Major Player Table 3. Chemotherapy Major Player Table 4. Targeted Therapy Major Player Table 5. Global Neuroendocrine Carcinoma Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Oncology Centres Major Player Table 7. Clinics Major Player Table 8. Hospital Major Player Table 9. Ambulatory Surgery Centres Major Player Table 10. Neuroendocrine Carcinoma Industry Trends Table 11. Neuroendocrine Carcinoma Industry Drivers Table 12. Neuroendocrine Carcinoma Industry Opportunities and Challenges Table 13. Neuroendocrine Carcinoma Industry Restraints Table 14. Global Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Neuroendocrine Carcinoma Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Neuroendocrine Carcinoma Market Share by Region (2021-2026) Table 17. Global Neuroendocrine Carcinoma Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Neuroendocrine Carcinoma Market Share by Region (2027-2032) Table 19. Global Neuroendocrine Carcinoma Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Neuroendocrine Carcinoma Revenue Market Share by Players (2021-2026) Table 21. Global Neuroendocrine Carcinoma Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Neuroendocrine Carcinoma Key Players Headquarters & Area Served Table 23. Global Neuroendocrine Carcinoma Players, Product Type & Application Table 24. Global Neuroendocrine Carcinoma Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Neuroendocrine Carcinoma by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Neuroendocrine Carcinoma Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Neuroendocrine Carcinoma Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2021-2026) Table 31. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2027-2032) Table 32. Global Neuroendocrine Carcinoma Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Neuroendocrine Carcinoma Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2021-2026) Table 36. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2027-2032) Table 37. Teva Company Information Table 38. Teva Business Overview Table 39. Teva Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Teva Neuroendocrine Carcinoma Product Portfolio Table 41. Teva Recent Development Table 42. Novartis Company Information Table 43. Novartis Business Overview Table 44. Novartis Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Novartis Neuroendocrine Carcinoma Product Portfolio Table 46. Novartis Recent Development Table 47. Pfizer Company Information Table 48. Pfizer Business Overview Table 49. Pfizer Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Pfizer Neuroendocrine Carcinoma Product Portfolio Table 51. Pfizer Recent Development Table 52. Abbvie Company Information Table 53. Abbvie Business Overview Table 54. Abbvie Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Abbvie Neuroendocrine Carcinoma Product Portfolio Table 56. Abbvie Recent Development Table 57. Valeant Company Information Table 58. Valeant Business Overview Table 59. Valeant Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Valeant Neuroendocrine Carcinoma Product Portfolio Table 61. Valeant Recent Development Table 62. Mateon Company Information Table 63. Mateon Business Overview Table 64. Mateon Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Mateon Neuroendocrine Carcinoma Product Portfolio Table 66. Mateon Recent Development Table 67. Lexicon Company Information Table 68. Lexicon Business Overview Table 69. Lexicon Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Lexicon Neuroendocrine Carcinoma Product Portfolio Table 71. Lexicon Recent Development Table 72. Jubilant Company Information Table 73. Jubilant Business Overview Table 74. Jubilant Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Jubilant Neuroendocrine Carcinoma Product Portfolio Table 76. Jubilant Recent Development Table 77. Ipsen Company Information Table 78. Ipsen Business Overview Table 79. Ipsen Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Ipsen Neuroendocrine Carcinoma Product Portfolio Table 81. Ipsen Recent Development Table 82. F.Hoffmann-La Roche Company Information Table 83. F.Hoffmann-La Roche Business Overview Table 84. F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Portfolio Table 86. F.Hoffmann-La Roche Recent Development Table 87. Chiasma Company Information Table 88. Chiasma Business Overview Table 89. Chiasma Neuroendocrine Carcinoma Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Chiasma Neuroendocrine Carcinoma Product Portfolio Table 91. Chiasma Recent Development Table 92. Advanced Accelerator Company Information Table 93. Advanced Accelerator Business Overview Table 94. Advanced Accelerator Neuroendocrine Carcinoma Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Advanced Accelerator Neuroendocrine Carcinoma Product Portfolio Table 96. Advanced Accelerator Recent Development Table 97. North America Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (US$ Million) Table 98. North America Neuroendocrine Carcinoma Revenue by Type (2027-2032) & (US$ Million) Table 99. North America Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (US$ Million) Table 100. North America Neuroendocrine Carcinoma Revenue by Application (2027-2032) & (US$ Million) Table 101. North America Neuroendocrine Carcinoma Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. North America Neuroendocrine Carcinoma Revenue by Country (2021-2026) & (US$ Million) Table 103. North America Neuroendocrine Carcinoma Revenue by Country (US$ Million) & (2027-2032) Table 104. Europe Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (US$ Million) Table 105. Europe Neuroendocrine Carcinoma Revenue by Type (2027-2032) & (US$ Million) Table 106. Europe Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (US$ Million) Table 107. Europe Neuroendocrine Carcinoma Revenue by Application (2027-2032) & (US$ Million) Table 108. Europe Neuroendocrine Carcinoma Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Europe Neuroendocrine Carcinoma Revenue by Country (2021-2026) & (US$ Million) Table 110. Europe Neuroendocrine Carcinoma Revenue by Country (US$ Million) & (2027-2032) Table 111. China Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (US$ Million) Table 112. China Neuroendocrine Carcinoma Revenue by Type (2027-2032) & (US$ Million) Table 113. China Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (US$ Million) Table 114. China Neuroendocrine Carcinoma Revenue by Application (2027-2032) & (US$ Million) Table 115. Asia Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (US$ Million) Table 116. Asia Neuroendocrine Carcinoma Revenue by Type (2027-2032) & (US$ Million) Table 117. Asia Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (US$ Million) Table 118. Asia Neuroendocrine Carcinoma Revenue by Application (2027-2032) & (US$ Million) Table 119. Asia Neuroendocrine Carcinoma Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Asia Neuroendocrine Carcinoma Revenue by Region (US$ Million) & (2021-2026) Table 121. Asia Neuroendocrine Carcinoma Revenue by Region (US$ Million) & (2027-2032) Table 122. SAMEA Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (US$ Million) Table 123. SAMEA Neuroendocrine Carcinoma Revenue by Type (2027-2032) & (US$ Million) Table 124. SAMEA Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (US$ Million) Table 125. SAMEA Neuroendocrine Carcinoma Revenue by Application (2027-2032) & (US$ Million) Table 126. SAMEA Neuroendocrine Carcinoma Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. SAMEA Neuroendocrine Carcinoma Revenue by Country (2021-2026) & (US$ Million) Table 128. SAMEA Neuroendocrine Carcinoma Revenue by Country (US$ Million) & (2027-2032) Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Neuroendocrine Carcinoma Image Figure 2. Global Neuroendocrine Carcinoma Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Carcinoma Market Size Share 2021 VS 2025 VS 2032 Figure 4. Somatostatin Analogs Image Figure 5. Chemotherapy Image Figure 6. Targeted Therapy Image Figure 7. Global Neuroendocrine Carcinoma Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Neuroendocrine Carcinoma Market Size Share 2021 VS 2025 VS 2032 Figure 9. Oncology Centres Image Figure 10. Clinics Image Figure 11. Hospital Image Figure 12. Ambulatory Surgery Centres Image Figure 13. Global Neuroendocrine Carcinoma Market Size (US$ Million) & (2021-2032) Figure 14. Global Neuroendocrine Carcinoma Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Neuroendocrine Carcinoma Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Neuroendocrine Carcinoma Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Neuroendocrine Carcinoma Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Neuroendocrine Carcinoma Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2021-2032) Figure 21. Global Neuroendocrine Carcinoma Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2021-2032) Figure 24. North America Neuroendocrine Carcinoma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Neuroendocrine Carcinoma Revenue Share by Type (2021-2032) Figure 26. North America Neuroendocrine Carcinoma Revenue Share by Application (2021-2032) Figure 27. North America Neuroendocrine Carcinoma Revenue Share by Country (2021-2032) Figure 28. United States Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Neuroendocrine Carcinoma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Neuroendocrine Carcinoma Revenue Share by Type (2021-2032) Figure 33. Europe Neuroendocrine Carcinoma Revenue Share by Application (2021-2032) Figure 34. Europe Neuroendocrine Carcinoma Revenue Share by Country (2021-2032) Figure 35. Germany Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Neuroendocrine Carcinoma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Neuroendocrine Carcinoma Revenue Share by Type (2021-2032) Figure 45. China Neuroendocrine Carcinoma Revenue Share by Application (2021-2032) Figure 46. Asia Neuroendocrine Carcinoma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Neuroendocrine Carcinoma Revenue Share by Type (2021-2032) Figure 48. Asia Neuroendocrine Carcinoma Revenue Share by Application (2021-2032) Figure 49. Asia Neuroendocrine Carcinoma Revenue Share by Region (2021-2032) Figure 50. Japan Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Neuroendocrine Carcinoma Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Neuroendocrine Carcinoma Revenue Share by Type (2021-2032) Figure 58. SAMEA Neuroendocrine Carcinoma Revenue Share by Application (2021-2032) Figure 59. SAMEA Neuroendocrine Carcinoma Revenue Share by Country (2021-2032) Figure 60. Brazil Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Neuroendocrine Carcinoma Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Somatostatin Analogs
  • Chemotherapy
  • Targeted Therapy
Applications
  • Oncology Centres
  • Clinics
  • Hospital
  • Ambulatory Surgery Centres
Companies covered
  • Teva
  • Novartis
  • Pfizer
  • Abbvie
  • Valeant
  • Mateon
  • Lexicon
  • Jubilant
  • Ipsen
  • F.Hoffmann-La Roche
  • Chiasma
  • Advanced Accelerator

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neuroendocrine Carcinoma Market by Type
  3. 1.2.1 Global Neuroendocrine Carcinoma Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Somatostatin Analogs
  5. 1.2.3 Chemotherapy
  6. 1.2.4 Targeted Therapy
  7. 1.3 Neuroendocrine Carcinoma Market by Application
  8. 1.3.1 Global Neuroendocrine Carcinoma Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology Centres
  10. 1.3.3 Clinics
  11. 1.3.4 Hospital
  12. 1.3.5 Ambulatory Surgery Centres
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Neuroendocrine Carcinoma Market Dynamics
  1. 2.1 Neuroendocrine Carcinoma Industry Trends
  2. 2.2 Neuroendocrine Carcinoma Industry Drivers
  3. 2.3 Neuroendocrine Carcinoma Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Carcinoma Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neuroendocrine Carcinoma Market Perspective (2021-2032)
  2. 3.2 Global Neuroendocrine Carcinoma Growth Trends by Region
  3. 3.2.1 Global Neuroendocrine Carcinoma Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neuroendocrine Carcinoma Market Size by Region (2021-2026)
  5. 3.2.3 Global Neuroendocrine Carcinoma Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neuroendocrine Carcinoma Revenue by Players
  2. 4.1.1 Global Neuroendocrine Carcinoma Revenue by Players (2021-2026)
  3. 4.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neuroendocrine Carcinoma Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neuroendocrine Carcinoma Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neuroendocrine Carcinoma Key Players Headquarters & Area Served
  7. 4.4 Global Neuroendocrine Carcinoma Players, Product Type & Application
  8. 4.5 Global Neuroendocrine Carcinoma Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neuroendocrine Carcinoma Market CR5 and HHI
  11. 4.6.3 2025 Neuroendocrine Carcinoma Tier 1, Tier 2, and Tier 3
5 Neuroendocrine Carcinoma Market Size by Type
  1. 5.1 Global Neuroendocrine Carcinoma Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neuroendocrine Carcinoma Revenue by Type (2021-2032)
  3. 5.3 Global Neuroendocrine Carcinoma Revenue Market Share by Type (2021-2032)
6 Neuroendocrine Carcinoma Market Size by Application
  1. 6.1 Global Neuroendocrine Carcinoma Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neuroendocrine Carcinoma Revenue by Application (2021-2032)
  3. 6.3 Global Neuroendocrine Carcinoma Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva
  2. 7.1.1 Teva Company Information
  3. 7.1.2 Teva Business Overview
  4. 7.1.3 Teva Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Neuroendocrine Carcinoma Product Portfolio
  6. 7.1.5 Teva Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Neuroendocrine Carcinoma Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Neuroendocrine Carcinoma Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 Abbvie
  20. 7.4.1 Abbvie Company Information
  21. 7.4.2 Abbvie Business Overview
  22. 7.4.3 Abbvie Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Abbvie Neuroendocrine Carcinoma Product Portfolio
  24. 7.4.5 Abbvie Recent Developments
  25. 7.5 Valeant
  26. 7.5.1 Valeant Company Information
  27. 7.5.2 Valeant Business Overview
  28. 7.5.3 Valeant Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Valeant Neuroendocrine Carcinoma Product Portfolio
  30. 7.5.5 Valeant Recent Developments
  31. 7.6 Mateon
  32. 7.6.1 Mateon Company Information
  33. 7.6.2 Mateon Business Overview
  34. 7.6.3 Mateon Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Mateon Neuroendocrine Carcinoma Product Portfolio
  36. 7.6.5 Mateon Recent Developments
  37. 7.7 Lexicon
  38. 7.7.1 Lexicon Company Information
  39. 7.7.2 Lexicon Business Overview
  40. 7.7.3 Lexicon Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Lexicon Neuroendocrine Carcinoma Product Portfolio
  42. 7.7.5 Lexicon Recent Developments
  43. 7.8 Jubilant
  44. 7.8.1 Jubilant Company Information
  45. 7.8.2 Jubilant Business Overview
  46. 7.8.3 Jubilant Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Jubilant Neuroendocrine Carcinoma Product Portfolio
  48. 7.8.5 Jubilant Recent Developments
  49. 7.9 Ipsen
  50. 7.9.1 Ipsen Company Information
  51. 7.9.2 Ipsen Business Overview
  52. 7.9.3 Ipsen Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Ipsen Neuroendocrine Carcinoma Product Portfolio
  54. 7.9.5 Ipsen Recent Developments
  55. 7.10 F.Hoffmann-La Roche
  56. 7.10.1 F.Hoffmann-La Roche Company Information
  57. 7.10.2 F.Hoffmann-La Roche Business Overview
  58. 7.10.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  59. 7.10.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Portfolio
  60. 7.10.5 F.Hoffmann-La Roche Recent Developments
  61. 7.11 Chiasma
  62. 7.11.1 Chiasma Company Information
  63. 7.11.2 Chiasma Business Overview
  64. 7.11.3 Chiasma Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Chiasma Neuroendocrine Carcinoma Product Portfolio
  66. 7.11.5 Chiasma Recent Developments
  67. 7.12 Advanced Accelerator
  68. 7.12.1 Advanced Accelerator Company Information
  69. 7.12.2 Advanced Accelerator Business Overview
  70. 7.12.3 Advanced Accelerator Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Advanced Accelerator Neuroendocrine Carcinoma Product Portfolio
  72. 7.12.5 Advanced Accelerator Recent Developments
8 North America
  1. 8.1 North America Neuroendocrine Carcinoma Revenue (2021-2032)
  2. 8.2 North America Neuroendocrine Carcinoma Revenue by Type (2021-2032)
  3. 8.2.1 North America Neuroendocrine Carcinoma Revenue by Type (2021-2026)
  4. 8.2.2 North America Neuroendocrine Carcinoma Revenue by Type (2027-2032)
  5. 8.3 North America Neuroendocrine Carcinoma Revenue Share by Type (2021-2032)
  6. 8.4 North America Neuroendocrine Carcinoma Revenue by Application (2021-2032)
  7. 8.4.1 North America Neuroendocrine Carcinoma Revenue by Application (2021-2026)
  8. 8.4.2 North America Neuroendocrine Carcinoma Revenue by Application (2027-2032)
  9. 8.5 North America Neuroendocrine Carcinoma Revenue Share by Application (2021-2032)
  10. 8.6 North America Neuroendocrine Carcinoma Revenue by Country
  11. 8.6.1 North America Neuroendocrine Carcinoma Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neuroendocrine Carcinoma Revenue by Country (2021-2026)
  13. 8.6.3 North America Neuroendocrine Carcinoma Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Neuroendocrine Carcinoma Revenue (2021-2032)
  2. 9.2 Europe Neuroendocrine Carcinoma Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neuroendocrine Carcinoma Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neuroendocrine Carcinoma Revenue by Type (2027-2032)
  5. 9.3 Europe Neuroendocrine Carcinoma Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neuroendocrine Carcinoma Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neuroendocrine Carcinoma Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neuroendocrine Carcinoma Revenue by Application (2027-2032)
  9. 9.5 Europe Neuroendocrine Carcinoma Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neuroendocrine Carcinoma Revenue by Country
  11. 9.6.1 Europe Neuroendocrine Carcinoma Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neuroendocrine Carcinoma Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neuroendocrine Carcinoma Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Neuroendocrine Carcinoma Revenue (2021-2032)
  2. 10.2 China Neuroendocrine Carcinoma Revenue by Type (2021-2032)
  3. 10.2.1 China Neuroendocrine Carcinoma Revenue by Type (2021-2026)
  4. 10.2.2 China Neuroendocrine Carcinoma Revenue by Type (2027-2032)
  5. 10.3 China Neuroendocrine Carcinoma Revenue Share by Type (2021-2032)
  6. 10.4 China Neuroendocrine Carcinoma Revenue by Application (2021-2032)
  7. 10.4.1 China Neuroendocrine Carcinoma Revenue by Application (2021-2026)
  8. 10.4.2 China Neuroendocrine Carcinoma Revenue by Application (2027-2032)
  9. 10.5 China Neuroendocrine Carcinoma Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neuroendocrine Carcinoma Revenue (2021-2032)
  2. 11.2 Asia Neuroendocrine Carcinoma Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neuroendocrine Carcinoma Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neuroendocrine Carcinoma Revenue by Type (2027-2032)
  5. 11.3 Asia Neuroendocrine Carcinoma Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neuroendocrine Carcinoma Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neuroendocrine Carcinoma Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neuroendocrine Carcinoma Revenue by Application (2027-2032)
  9. 11.5 Asia Neuroendocrine Carcinoma Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neuroendocrine Carcinoma Revenue by Country
  11. 11.6.1 Asia Neuroendocrine Carcinoma Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neuroendocrine Carcinoma Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neuroendocrine Carcinoma Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neuroendocrine Carcinoma Revenue (2021-2032)
  2. 12.2 SAMEA Neuroendocrine Carcinoma Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neuroendocrine Carcinoma Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neuroendocrine Carcinoma Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neuroendocrine Carcinoma Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neuroendocrine Carcinoma Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neuroendocrine Carcinoma Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neuroendocrine Carcinoma Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neuroendocrine Carcinoma Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neuroendocrine Carcinoma Revenue by Country
  11. 12.6.1 SAMEA Neuroendocrine Carcinoma Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neuroendocrine Carcinoma Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neuroendocrine Carcinoma Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst